Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus

Annals of the Rheumatic Diseases

Volumn 66, Issue 5, 2007, Pages 569-570

  Mukhtyar, Chetan ^a   Boumpas, Dimitrios ^b   Gordon, Caroline ^c   Gross, Wolfgang ^d   Jayne, David ^e   Luqmani, Raashid ^a,f  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF CRETE   (Greece)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e ADDENBROOKE S HOSPITAL   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COTRIMOXAZOLE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; STEROID;

ANCA ASSOCIATED VASCULITIS; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DRUG EFFICACY; ECONOMIC ASPECT; EDITORIAL; HEALTH PRACTITIONER; HUMAN; NURSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; STRESS; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

CLINICAL TRIALS; GUIDELINES; HEALTH CARE COSTS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RESEARCH DESIGN; TREATMENT OUTCOME; VASCULITIS;

EID: 34248202661     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.065854     Document Type: Editorial

References (18)

1. de Groot K, Adu D, Savage CO. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001;16:2018-27.
2. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2004;43:197-208.
3. Boumpas DT, Sidiropoulos P, Bertsias G. Optimum therapeutic approaches for lupus nephritis: what therapy and for whom? Nat Clin Pract Rheumatol 2005;1:22-30.
4. Karassa FB, Tatsioni A, Ioannidis JP. Design, quality, and bias in randomized controlled trials of systemic lupus erythematosus. J Rheumatol 2003;30:979-84.
5. Gordon C, Bertsias G, Ioannidis JP, Boumpas DT. EULAR recommendations for conducting clinical trials in SLE. Ann Rheum Dis 2006;65(Suppl 2):2.
6. Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: Focus on ANCA-associated vasculitis. Ann Rheum Dis 2006; Published Online First. 14 December 2006. doi: 10.1136/ard.2006.062711.
7. Timmermans S. From autonomy to accountability: the role of clinical practice guidelines in professional power. Perspect Biol Med 2005;48:490-501.
8. Jennette JC, Falk PJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187- 92.
9. Fries JF, Hunder GG, Bloch DA, Michel BA, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 1990;33:1135-6.
10. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
11. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-80.
12. Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001;44:912-20.
13. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671-8.
14. de Groot K, Gross WL, Herlyn K, Reinhold-Keller E. Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol 2001;55:31-8.
15. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58.
16. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
17. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SUCC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000;27:373-6.
18. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.